Allogeneic stem cell transplantation may overcome the adverse impact of myelofibrosis on the prognosis of myelodysplastic syndrome

Table 5 Results of stem cell transplantation in MDS patients with MF = 0/1 or MF = 2/3 (n = 141)

	MF = 0/1) (n = 121)	MF = 2/3 (n = 20)	P
Cumulative incidence of neutrophil reconstruction at day + 30	98.3%	95.0%	0.107
Cumulative incidence of platelet reconstruction at day + 30	87.6%	80.0%	0.303
Median days to neutrophil reconstruction(> 0.5 × 10⁹/L) (range)	12(7–34)	14(10–45)	0.005
Median days to platelet reconstruction(> 20X10⁹/L) (range)	14(8–68)	18(8–65)	0.045
Acute GVHD grade II–IV	45(37.2%)	6(30%)	0.535
Chronic GVHD	67(55.4%)	10(50%)	0.655
2 year cumulative incidence of relapse	12.0%	16.8%	0.910
2 year non-replase mortality	26.0%	21.7%	0.441

ISSN: 2162-3619